Bio Protocol, also referred to simply as Bio, is a DeSci (decentralized science) network that lets scientists convert their work into autonomous on-chain AI agents called BioAgents. These BioAgents can mint hypotheses, raise capital via token sales, and share data transparently, aiming to compress drug-development timelines from decades to months. The company’s first BioAgent, Aubrai, has already minted more than 1,000 hypotheses and secured $250,000 in research funding, with its token briefly rising 150× from a $269,000 pre-sale valuation to a roughly $40 million peak. Bio recently launched its V2 platform, adding Ignition Sales for rapid tokenized fundraises, a staking and rewards program (BioXP), and support for future agents in dermatology, microbiome, brain health, and men’s health. The protocol’s native BIO token trades around $0.16, giving it a market cap of about $309 million. According to the company, projects across its network have already directed over $50 million to labs worldwide. With fresh capital, Bio plans to broaden its BioAgent framework globally, creating a network of decentralized AI “science machines.”

Total raised

$7M

Funding rounds

2

Latest round

Seed

Latest activity

Sep 2025